{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:36:58Z","timestamp":1790779018026,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the National Cancer Center Research and Development Fund","award":["(29-A-3)"],"award-info":[{"award-number":["(29-A-3)"]}]},{"name":"Health and Labor Sciences Research Gant","award":["(H29-013"],"award-info":[{"award-number":["(H29-013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type 1 (NF1) is a genetic multisystem disorder. Clinicians must be aware of the diverse clinical features of this disorder in order to provide optimal care for it. We have set up an NF1 in-hospital medical care network of specialists regardless of patient age, launching a multidisciplinary approach to the disease for the first time in Japan. From January 2014 to December 2020, 246 patients were enrolled in the NF1 patient list and medical records. Mean age was 26.0\u00a0years ranging from 3\u00a0months to 80\u00a0years. The number of patients was higher as\u00a0age at first visit was lower. There were 107 males (41%) and 139 females. After 2011, the number of patients has increased since the year when the medical care network was started. Regarding orthopedic signs, scoliosis was present in 60 cases (26%), and bone abnormalities in the upper arm, forearm, and tibia in 8 cases (3.5%). Neurofibromas other than cutaneous neurofibromas were present in 90 cases (39%), and MPNST in 17 cases (7.4%). We launched a multidisciplinary NF1 clinic system for the first time in Japan. For patients with NF1, which is a hereditary and systemic disease associated with a high incidence of malignant tumors, it will be of great benefit when the number of such clinics in Japan and the rest of Asia is increased.<\/jats:p>","DOI":"10.1038\/s41598-021-91345-6","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T10:06:06Z","timestamp":1623060366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Establishment of in-hospital clinical network for patients with neurofibromatosis type 1 in Nagoya University Hospital"],"prefix":"10.1038","volume":"11","author":[{"given":"Yoshihiro","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Ikuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Natsume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kidokoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Nonobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Takeichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Kanbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Imagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"Pt 6","key":"91345_CR1","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/111.6.1355","volume":"111","author":"SM Huson","year":"1988","unstructured":"Huson, S. M., Harper, P. S. & Compston, D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain J. Neurol. 111(Pt 6), 1355\u20131381 (1988).","journal-title":"Brain J. Neurol."},{"issue":"1","key":"91345_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archderm.141.1.71","volume":"141","author":"M Lammert","year":"2005","unstructured":"Lammert, M., Friedman, J. M., Kluwe, L. & Mautner, V. F. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch. Dermatol. 141(1), 71\u201374 (2005).","journal-title":"Arch. Dermatol."},{"issue":"5","key":"91345_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/archneur.1988.00520290115023","volume":"45","author":"Neurofibromatosis","year":"1988","unstructured":"Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 45(5), 575\u2013578 (1988).","journal-title":"Arch. Neurol."},{"issue":"2","key":"91345_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"JM Friedman","year":"1997","unstructured":"Friedman, J. M. & Birch, P. H. Type 1 neurofibromatosis: A descriptive analysis of the disorder in 1728 patients. Am. J. Med. Genet. 70(2), 138\u2013143 (1997).","journal-title":"Am. J. Med. Genet."},{"issue":"Pt 3","key":"91345_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/brain\/122.3.473","volume":"122","author":"A Creange","year":"1999","unstructured":"Creange, A. et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain J Neurol. 122(Pt 3), 473\u2013481 (1999).","journal-title":"Brain J Neurol."},{"issue":"1\u20132","key":"91345_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0022-510X(96)00022-6","volume":"138","author":"RE Ferner","year":"1996","unstructured":"Ferner, R. E., Hughes, R. A. & Weinman, J. Intellectual impairment in neurofibromatosis 1. J. Neurol. Sci. 138(1\u20132), 125\u2013133 (1996).","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"91345_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/GIM.0b013e3181bf15e3","volume":"12","author":"K Jett","year":"2010","unstructured":"Jett, K. & Friedman, J. M. Clinical and genetic aspects of neurofibromatosis 1. Genet. Med. 12(1), 1\u201311 (2010).","journal-title":"Genet. Med."},{"issue":"2","key":"91345_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/jnnp.2010.206532","volume":"10","author":"RE Ferner","year":"2010","unstructured":"Ferner, R. E. The neurofibromatoses. Pract. Neurol. 10(2), 82\u201393 (2010).","journal-title":"Pract. Neurol."},{"issue":"5","key":"91345_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39(5), 311\u2013314 (2002).","journal-title":"J. Med. Genet."},{"issue":"7","key":"91345_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/jmg.2006.048140","volume":"44","author":"JA McCaughan","year":"2007","unstructured":"McCaughan, J. A., Holloway, S. M., Davidson, R. & Lam, W. W. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J. Med. Genet. 44(7), 463\u2013466 (2007).","journal-title":"J. Med. Genet."},{"issue":"12","key":"91345_CR11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00432-010-0846-3","volume":"136","author":"G Spurlock","year":"2010","unstructured":"Spurlock, G. et al. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: Correlation between histopathological, clinical and molecular findings. J. Cancer Res. Clin. Oncol. 136(12), 1869\u20131880 (2010).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"91345_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog, O. O. & Goldacre, M. J. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: Population-based record-linkage study. Br. J. Cancer 108(1), 193\u2013198 (2013).","journal-title":"Br. J. Cancer"},{"issue":"3","key":"91345_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11910-009-0036-3","volume":"9","author":"K Yohay","year":"2009","unstructured":"Yohay, K. Neurofibromatosis type 1 and associated malignancies. Curr. Neurol. Neurosci. Rep. 9(3), 247\u2013253 (2009).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"11","key":"91345_CR14","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2125::AID-CNCR9>3.0.CO;2-N","volume":"79","author":"ME Zoller","year":"1997","unstructured":"Zoller, M. E., Rembeck, B., Oden, A., Samuelsson, M. & Angervall, L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79(11), 2125\u20132131 (1997).","journal-title":"Cancer"},{"issue":"11","key":"91345_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","volume":"19","author":"DG Evans","year":"2011","unstructured":"Evans, D. G. et al. Mortality in neurofibromatosis 1: In North West England: An assessment of actuarial survival in a region of the UK since 1989. Eur. J. Hum. Genet. 19(11), 1187\u20131191 (2011).","journal-title":"Eur. J. Hum. Genet."},{"key":"91345_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1750-1172-6-11","volume":"6","author":"M Masocco","year":"2011","unstructured":"Masocco, M. et al. Mortality associated with neurofibromatosis type 1: A study based on Italian death certificates (1995\u20132006). Orphan. J. Rare Dis. 6, 11 (2011).","journal-title":"Orphan. J. Rare Dis."},{"issue":"1","key":"91345_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12913-018-3471-5","volume":"18","author":"VL Merker","year":"2018","unstructured":"Merker, V. L. et al. Increasing access to specialty care for rare diseases: A case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv. Res. 18(1), 668 (2018).","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"91345_CR18","first-page":"160","volume":"77","author":"K McKeever","year":"2008","unstructured":"McKeever, K., Shepherd, C. W., Crawford, H. & Morrison, P. J. An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulst. Med. J. 77(3), 160\u2013163 (2008).","journal-title":"Ulst. Med. J."},{"issue":"1\u20132","key":"91345_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1440-1754.2007.01003.x","volume":"43","author":"F Noble","year":"2007","unstructured":"Noble, F., Kornberg, A. J., Elder, J. E. & Delatycki, M. B. Retrospective analysis of patients attending a neurofibromatosis type 1 clinic. J. Paediatr. Child Health 43(1\u20132), 55\u201359 (2007).","journal-title":"J. Paediatr. Child Health"},{"issue":"4","key":"91345_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ajmg.a.35840","volume":"161a","author":"EC Oates","year":"2013","unstructured":"Oates, E. C., Payne, J. M., Foster, S. L., Clarke, N. F. & North, K. N. Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge. Am. J. Med. Genet. Part A. 161a(4), 659\u2013666 (2013).","journal-title":"Am. J. Med. Genet. Part A."},{"issue":"5","key":"91345_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1017\/cjn.2016.326","volume":"44","author":"A Mansouri","year":"2017","unstructured":"Mansouri, A. et al. Neurofibromatosis clinic: A report on patient demographics and evaluation of the clinic. Can. J. Neurol. Sci. 44(5), 577\u2013588 (2017).","journal-title":"Can. J. Neurol. Sci."},{"issue":"3","key":"91345_CR22","first-page":"134","volume":"1","author":"E Beckman","year":"1988","unstructured":"Beckman, E. & Akbarnia, B. A. The cardinal Glennon Children\u2019s Hospital neurofibromatosis clinic model. Neurofibromatosis 1(3), 134\u2013136 (1988).","journal-title":"Neurofibromatosis"},{"issue":"12","key":"91345_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/gim.2012.85","volume":"14","author":"DL Wang","year":"2012","unstructured":"Wang, D. L. et al. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet. Med. 14(12), 977\u2013982 (2012).","journal-title":"Genet. Med."},{"issue":"4","key":"91345_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/088307389300800421","volume":"8","author":"K North","year":"1993","unstructured":"North, K. Neurofibromatosis type 1: Review of the first 200 patients in an Australian clinic. J. Child Neurol. 8(4), 395\u2013402 (1993).","journal-title":"J. Child Neurol."},{"issue":"9","key":"91345_CR25","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1590\/S0100-879X2005000900020","volume":"38","author":"AB Trov\u00f3-Marqui","year":"2005","unstructured":"Trov\u00f3-Marqui, A. B. et al. High frequencies of plexiform neurofibromas, mental retardation, learning difficulties, and scoliosis in Brazilian patients with neurofibromatosis type 1. Braz. J. Med. Biol. Res. 38(9), 1441\u20131447 (2005).","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"6","key":"91345_CR26","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1046\/j.1365-2133.2000.03543.x","volume":"142","author":"P Wolkenstein","year":"2000","unstructured":"Wolkenstein, P. et al. Cost evaluation of the medical management of neurofibromatosis 1: A prospective study on 201 patients. Br. J. Dermatol. 142(6), 1166\u20131170 (2000).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"91345_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/nrc2349","volume":"8","author":"A Bleyer","year":"2008","unstructured":"Bleyer, A. et al. The distinctive biology of cancer in adolescents and young adults. Nat. Rev. Cancer 8(4), 288\u2013298 (2008).","journal-title":"Nat. Rev. Cancer"},{"issue":"9159","key":"91345_CR28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(98)00155-X","volume":"353","author":"SM Huson","year":"1999","unstructured":"Huson, S. M. What level of care for the neurofibromatoses?. Lancet (Lond., Engl.). 353(9159), 1114\u20131116 (1999).","journal-title":"Lancet (Lond., Engl.)."},{"issue":"2","key":"91345_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner, R. E. et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44(2), 81\u201388 (2007).","journal-title":"J. Med. Genet."},{"issue":"4","key":"91345_CR30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1177\/1049732308314853","volume":"18","author":"E Giarelli","year":"2008","unstructured":"Giarelli, E., Bernhardt, B. A., Mack, R. & Pyeritz, R. E. Adolescents\u2019 transition to self-management of a chronic genetic disorder. Qual. Health Res. 18(4), 441\u2013457 (2008).","journal-title":"Qual. Health Res."},{"issue":"2","key":"91345_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pec.2010.05.031","volume":"83","author":"M Donald","year":"2011","unstructured":"Donald, M. et al. The role of patient activation in frequent attendance at primary care: A population-based study of people with chronic disease. Patient Educ. Couns. 83(2), 217\u2013221 (2011).","journal-title":"Patient Educ. Couns."},{"issue":"2","key":"91345_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1377\/hlthaff.2012.1061","volume":"32","author":"JH Hibbard","year":"2013","unstructured":"Hibbard, J. H. & Greene, J. What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs. Health Affairs (Project Hope) 32(2), 207\u2013214 (2013).","journal-title":"Health Affairs (Project Hope)"},{"issue":"1","key":"91345_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004479-200701000-00005","volume":"30","author":"DM Mosen","year":"2007","unstructured":"Mosen, D. M. et al. Is patient activation associated with outcomes of care for adults with chronic conditions?. J. Ambulatory Care Manag. 30(1), 21\u201329 (2007).","journal-title":"J. Ambulatory Care Manag."},{"issue":"1","key":"91345_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-021-01711-w","volume":"16","author":"HB Radtke","year":"2021","unstructured":"Radtke, H. B. et al. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphan. J. Rare Dis. 16(1), 61 (2021).","journal-title":"Orphan. J. Rare Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91345-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91345-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:13:04Z","timestamp":1670058784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-91345-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["91345"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-91345-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11933"}}